Chemistry:LY2181308

From HandWiki
Revision as of 01:07, 12 August 2021 by imported>LinXED (fix)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

LY2181308 is an antisense oligonucleotide that complementarily binds to survivin mRNA and inhibits its expression in tumor tissue.[1]

It being investigated for a number of different cancers.[2]

It is targeted at survivin which prevents cells dying.[3]

Clinical trials

It has completed a phase II trial for acute myeloid leukemia.[4]

A phase II trial for non-small cell lung cancer has started.[5]

A phase II trial for hormone-refractory prostate cancer will run until early 2012.[6]

References